Peak Retirement Planning Inc. Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Peak Retirement Planning Inc. bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,238 shares of the medical equipment provider's stock, valued at approximately $917,000.

Several other large investors also recently made changes to their positions in LNTH. Janus Henderson Group PLC boosted its position in shares of Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after purchasing an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after purchasing an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after acquiring an additional 435,445 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Lantheus during the 4th quarter valued at about $36,183,000. Finally, Swedbank AB raised its position in Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after acquiring an additional 385,000 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

LNTH has been the subject of a number of research analyst reports. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Truist Financial lowered their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $132.67.

Insider Activity

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock worth $6,016,046 over the last quarter. 2.00% of the stock is currently owned by company insiders.

Lantheus Stock Performance

LNTH traded up $1.90 during trading on Tuesday, reaching $75.76. 949,727 shares of the company's stock were exchanged, compared to its average volume of 988,343. The company's fifty day moving average price is $93.51 and its 200-day moving average price is $91.90. The firm has a market capitalization of $5.24 billion, a PE ratio of 12.61 and a beta of 0.23. Lantheus Holdings, Inc. has a fifty-two week low of $73.11 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business's revenue was up .8% compared to the same quarter last year. During the same period last year, the company earned $1.69 earnings per share. Research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.